New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good


Agreement Worth Potentially 5 Billion Yen for the VR Healthcare Market

Jolly Good Inc. and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director: Makoto Inoue) have signed an agreement for exclusive product joint development and sales in Japan for a social skill training VR (“SST VR”) business. If including a 300 millon yen upfront payment from Otsuka Pharmaceutical to Jolly Good, as well as development cost reimbursement and royalties, the deal is worth 5 billion yen.

Press Release